Overexpression of ABCB1 and ABCG2 in particular has been confirmed in CD34+CD38− leukemia stem cells [11,12], and it has been associated with poor prognosis and outcome of AML therapy [13,14,15]. The gene discussed is ABCG2; the disease is acute myeloid leukemia.